You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 錦欣生殖(1951.HK)逆勢漲4% 北京16項輔助生殖技術項目納入醫保報銷
格隆匯2月22日丨昨日大幅收漲8.77%的錦欣生殖(1951.HK)今日繼續走高,現漲4.09%報9.17港元,暫成交5億港元,最新市值230億港元;同為輔助生殖概念股的貝康醫療(2170.HK)亦逆勢漲近3%。消息面上,北京市醫保局近日會同市衞生健康委、市人力社保局印發《關於規範調整部分醫療服務價格項目的通知》。其中,為實施積極生育支持措施,通過組織專家論證,在費用可控、確保醫保基金可承受的基礎上,將門診治療中常見的宮腔內人工授精術、胚胎移植術、精子優選處理等16項涉及人羣廣、診療必需、技術成熟、安全可靠的輔助生殖技術項目納入醫保甲類報銷範圍。有分析人士指出,通知的印發意味着監管重拳方案落地,在政策層面上重視輔助生殖行業;參考日韓歐美,此舉有望帶動輔助生殖行業滲透率大大提升,提高行業規模。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account